Scholarlink

Purpose <p>This study aimed to assess the six-month outcomes of patients with pachychoroid neovasculopathy (PNV) treated with half-fluence photodynamic therapy (PDT) along with a single intravitreal aflibercept injection (IVA) and to identify factors linked to persistent or recurrent subretinal fluid (SRF).</p> Methods <p>This retrospective study included consecutive treatment-naïve PNV patients who received initial treatment with IVA and half-fluence PDT and were followed up for more than six months. Patient data, including sex, age, and baseline best-corrected visual acuity (BCVA), and imaging data, including optical coherence tomography (OCT), OCT angiography, and fundus autofluorescence (FAF), were retrospectively collected. BCVA, central macular thickness (CMT), and central choroidal thickness (CCT) were compared before and after the treatment. Additionally, we investigated factors linked to persistent or recurrent SRF.</p> Results <p>63 eyes of 63 patients were included in this study. The mean BCVA before treatment was 0.13 ± 0.23 logMAR, which improved to 0.04 ± 0.18 after six months. Additionally, the CMT and CCT before treatment significantly decreased. Persistent or recurrent SRF was observed in 21 patients (33%). These patients were older and demonstrated worse baseline BCVA, larger macular neovascularization (MNV), and greater hyperfluorescent areas on FAF.</p> Conclusion <p>Although half-fluence PDT along with IVA effectively improved BCVA, CMT, and CCT in patients with PNV, one-third of the patients required additional treatment due to persistent SRF. Older age, larger MNV, and worse baseline BCVA were linked to persistent SRF, underscoring the requirement for tailored treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Six-month outcomes of half-fluence photodynamic therapy combined with intravitreal Aflibercept injection for pachychoroid neovasculopathy

  • 期刊论文

  • 发表日期：

    2025年8月25日

查看全文
  • Yosuke Fukuda,
  • Satomi Shiose,
  • Shoji Notomi,
  • Yusuke Maehara,
  • Kenichiro Mori,
  • Kumiko Kano,
  • Keijiro Ishikawa,
  • Koh-Hei Sonoda

摘要

Purpose

This study aimed to assess the six-month outcomes of patients with pachychoroid neovasculopathy (PNV) treated with half-fluence photodynamic therapy (PDT) along with a single intravitreal aflibercept injection (IVA) and to identify factors linked to persistent or recurrent subretinal fluid (SRF).

Methods

This retrospective study included consecutive treatment-naïve PNV patients who received initial treatment with IVA and half-fluence PDT and were followed up for more than six months. Patient data, including sex, age, and baseline best-corrected visual acuity (BCVA), and imaging data, including optical coherence tomography (OCT), OCT angiography, and fundus autofluorescence (FAF), were retrospectively collected. BCVA, central macular thickness (CMT), and central choroidal thickness (CCT) were compared before and after the treatment. Additionally, we investigated factors linked to persistent or recurrent SRF.

Results

63 eyes of 63 patients were included in this study. The mean BCVA before treatment was 0.13 ± 0.23 logMAR, which improved to 0.04 ± 0.18 after six months. Additionally, the CMT and CCT before treatment significantly decreased. Persistent or recurrent SRF was observed in 21 patients (33%). These patients were older and demonstrated worse baseline BCVA, larger macular neovascularization (MNV), and greater hyperfluorescent areas on FAF.

Conclusion

Although half-fluence PDT along with IVA effectively improved BCVA, CMT, and CCT in patients with PNV, one-third of the patients required additional treatment due to persistent SRF. Older age, larger MNV, and worse baseline BCVA were linked to persistent SRF, underscoring the requirement for tailored treatment strategies.